What question did this study set out to answer?

To evaluate the clinical utility of RNA-based next-generation sequencing in diagnosing soft tissue sarcomas.

March 14, 2026Open Access

Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow

Key Points

To evaluate the clinical utility of RNA-based next-generation sequencing in diagnosing soft tissue sarcomas.
Single-center study with a multidisciplinary workflow
Integration of targeted RNA-based NGS
Assessment of diagnostic reclassification rates in sarcoma cases
Diagnostic reclassification achieved in 41.1% of evaluated cases
Notable improvement in round cell sarcomas with atypical morphology
Both canonical and rare fusions guided individualized therapy

Abstract

To our knowledge, this first-of-its-kind study highlights the clinical utility of integrating targeted RNA-based NGS into multidisciplinary sarcoma care, enabling diagnostic reclassification in 41.1% of cases most notably in round cell sarcomas with atypical morphology. Both canonical and rare fusions informed individualized therapy, reinforcing RNA-NGS as a pivotal tool for diagnostic refinement and precision oncology in sarcoma management.

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Sreenath et al. (Sun,) studied this question.

synapsesocial.com/papers/69b4ba3618185d8a39802ed3 https://doi.org/https://doi.org/10.1200/go-25-00440

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI에게 질문

Bookmark

View Full Paper